Latiglutenase for Celiac Disease

"Indeed, the information on clinicaltrials.gov suggests that this medical trial is enrolling participants at present. It was first published in April 2021 and received a recent update in August 2022; 40 individuals are expected to partake from one clinic."

"In this clinical trial, 40 individuals suffering from celiac disease and type 1 diabetes between 18-80 years old are being recruited. The primary prerequisites for applicants are: a confirmed CD diagnosis; presence of antibodies confirming T1D status; ongoing consumption of gluten free diet (for 12 months or more); occurrence of at least one moderate symptom in the last 28 days; consent to take study treatment every day, and agreement to sign informed consent form."

"It is estimated that Latiglutenase IMGX003 has a score of 2 for safety on a scale from 1 to 3 because this trial is currently in Phase 2, indicating there are some supporting data regarding its security but no evidence yet backing up its efficacy."

"The first clinical trials surrounding Latiglutenase IMGX003 began in 2019, led by Immunogenics, LLC. After its initial Phase 1 study with 120 participants, the drug gained approval to proceed into Phase 2 testing. At present, there are two active studies of this medication occurring across one nation's two major cities."

"Per the information on clinicaltrials.gov, this investigation is currently accepting volunteers and was first posted April 6th 2021 with a recent edit occurring August 2nd 2022."

"This medical study seeks out individuals over 18 yet below 80 years of age to be enrollees."

"Presently, two clinical trials are deployed to investigate the effects of Latiglutenase IMGX003. Neither of these studies is in Phase 3 yet. The research sites for this treatment are based mainly in Palo Alto, California but there exist other locations as well conducting similar investigations."